 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8081828384858687888990...100101» |
- carotuximab IV (ENV-105) / Kairos Pharma
Trial primary completion date, Metastases: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=35, Recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Feb 2018 --> Feb 2020
- | bicalutamide / Generic mfg.
Trial primary completion date, Metastases: Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2017
P2, N=58, Recruiting, Sponsor: Xu fei
Trial primary completion date: Feb 2018 --> Feb 2020 Trial primary completion date: Sep 2017 --> Sep 2018
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Dec 21, 2017
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Jul 2017 --> Jul 2018
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
New P3 trial: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Dec 19, 2017
P3, N=10000, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Soltamox (tamoxifen citrate) / Jazz
New P3 trial: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (clinicaltrials.gov) - Dec 19, 2017
P3, N=11248, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment open: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Dec 19, 2017
P3, N=10000, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2017 --> Jul 2018 Not yet recruiting --> Recruiting
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, PARP Biomarker: IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (clinicaltrials.gov) - Dec 19, 2017
P1, N=143, Not yet recruiting, Sponsor: Haukeland University Hospital
- | letrozole / Generic mfg.
Enrollment closed: RIOT-B: Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles (clinicaltrials.gov) - Dec 15, 2017
P2/3, N=33, Active, not recruiting, Sponsor: Sven O. Skouby
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Metastases: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] (clinicaltrials.gov) - Dec 14, 2017
P3, N=338, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial primary completion date: Combined Letrozole and Clomid in Women With Infertility and PCOS (clinicaltrials.gov) - Dec 14, 2017
P4, N=70, Recruiting, Sponsor: University of Iowa
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Mar 2018
- | Clinical: Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer (clinicaltrials.gov) - Dec 14, 2017
P2/3, N=200, Not yet recruiting, Sponsor: Zhiyong Yu
- | Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - Dec 13, 2017
P2, N=51, Active, not recruiting, Sponsor: International Breast Cancer Study Group
Trial primary completion date: Sep 2017 --> Mar 2018 Trial primary completion date: Aug 2017 --> Mar 2018
- | Soltamox (tamoxifen citrate) / Jazz
Trial initiation date, Trial primary completion date: Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (clinicaltrials.gov) - Dec 13, 2017
P4, N=600, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2017 --> Mar 2018 Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Sep 2022 --> Mar 2023
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Dec 12, 2017
P3, N=8028, Completed, Sponsor: International Breast Cancer Study Group
Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Sep 2022 --> Mar 2023 Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Enrollment open, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Dec 12, 2017
P1/2, N=40, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Trial primary completion date: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Dec 11, 2017
P2, N=299, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2018 --> May 2017
- | letrozole / Generic mfg., exemestane / Generic mfg.
Journal: Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. (Pubmed Central) - Dec 9, 2017
Letrozole had greater suppression of plasma E1 and E1S than exemestane, though the response was highly variable among patients. Additional research is required to examine the clinical relevance of differential estrogen suppression.
- | megestrol / Generic mfg.
Enrollment open, Metastases: MEGA: A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Dec 6, 2017
P2, N=20, Recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
Additional research is required to examine the clinical relevance of differential estrogen suppression. Not yet recruiting --> Recruiting
- imatinib / Generic mfg., letrozole / Generic mfg.
Trial primary completion date: Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 5, 2017
P2, N=45, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2018 --> Oct 2019
- | capecitabine / Generic mfg.
Enrollment open, Metastases: MECCA: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (clinicaltrials.gov) - Nov 29, 2017
P3, N=240, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Oct 2018 --> Oct 2019 Not yet recruiting --> Recruiting
- ||||| Ibrance (palbociclib) / Pfizer
New P4 trial, Real-world evidence, Real-world: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (clinicaltrials.gov) - Nov 28, 2017
P4, N=360, Not yet recruiting, Sponsor: German Breast Group
- || taselisib (GDC-0032) / Roche
Trial primary completion date, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Nov 27, 2017
P1/2, N=724, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2019 --> Nov 2022
- ||| PF-06804103 / Pfizer
Enrollment open: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Nov 21, 2017
P1, N=95, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2019 --> Nov 2022 Not yet recruiting --> Recruiting
- | Verzenio (abemaciclib) / Eli Lilly
Biomarker, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. (Pubmed Central) - Nov 16, 2017
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy...Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily...Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Nov 14, 2017
P3, N=3775, Recruiting, Sponsor: Novartis Pharmaceuticals
Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer. Initiation date: Jul 2015 --> Jul 2016
- | Trial primary completion date: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Nov 13, 2017
P3, N=249, Completed, Sponsor: Fudan University
Initiation date: Jul 2015 --> Jul 2016 Trial primary completion date: Oct 2017 --> Feb 2017
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Nov 6, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2017 --> Feb 2017 Trial primary completion date: Dec 2019 --> Dec 2020
- | letrozole / Generic mfg., exemestane / Generic mfg.
Journal: Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. (Pubmed Central) - Nov 3, 2017
If used in clinical practice, PROs might identify women at highest risk for early discontinuation and allow for interventions to improve tolerance before significant toxicities develop. Further research is needed to improve capturing PROs in routine clinical practice.
- | letrozole / Generic mfg.
Enrollment open, Trial primary completion date: Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) - Oct 31, 2017
P3, N=900, Recruiting, Sponsor: The University of Hong Kong
Further research is needed to improve capturing PROs in routine clinical practice. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion, Trial primary completion date: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Oct 31, 2017
P3, N=249, Completed, Sponsor: Fudan University
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Oct 30, 2017
P2, N=75, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017 Trial primary completion date: Sep 2017 --> Jan 2018
- ||||| Bizengri (zenocutuzumab-zbco) / Merus, Partner Therap
New P2 trial: MCLA-128-CL02: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. (clinicaltrials.gov) - Oct 26, 2017
P2, N=120, Not yet recruiting, Sponsor: Merus N.V.
- | Soltamox (tamoxifen citrate) / Jazz
Trial primary completion date: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (clinicaltrials.gov) - Oct 25, 2017
P3, N=11248, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Jan 2018 Trial primary completion date: Jun 2013 --> Dec 2017
- | sacibertinib (Hemay022) / Tianjin Hemay Pharma
Enrollment open, Combination therapy, Metastases: Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Oct 24, 2017
P1, N=48, Recruiting, Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd
Trial primary completion date: Jun 2013 --> Dec 2017 Not yet recruiting --> Recruiting
- | Piqray (alpelisib) / Novartis
Trial primary completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 23, 2017
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2017 --> Jan 2018
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Oct 20, 2017
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Oct 2017 --> Jan 2018 Trial primary completion date: Dec 2018 --> Dec 2020
- | Soltamox (tamoxifen citrate) / Jazz
Surgery: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (clinicaltrials.gov) - Oct 16, 2017
P3, N=10250, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Dec 2020 Trial primary completion date: Dec 2017 --> Jun 2013
- || Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Oct 16, 2017
P2, N=322, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Jun 2013 Trial primary completion date: Oct 2017 --> Jun 2017
- | Ibrance (palbociclib) / Pfizer
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: PALINA: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (clinicaltrials.gov) - Oct 16, 2017
P2/3, N=35, Recruiting, Sponsor: Georgetown University
Trial primary completion date: Oct 2017 --> Jun 2017 Initiation date: Jun 2016 --> Sep 2016 | Trial primary completion date: Jun 2018 --> Dec 2018
- | sacibertinib (Hemay022) / Tianjin Hemay Pharma
New P1 trial, Combination therapy, Metastases: Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Oct 11, 2017
P1, N=48, Not yet recruiting, Sponsor: Tianjin Hemay Pharmaceutical Co.,Ltd
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Metastases: Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone (clinicaltrials.gov) - Oct 11, 2017
P2, N=44, Active, not recruiting, Sponsor: Translational Research in Oncology
Initiation date: Jun 2016 --> Sep 2016 | Trial primary completion date: Jun 2018 --> Dec 2018 Trial primary completion date: Sep 2017 --> Dec 2017
- |||| Trial completion, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 5, 2017
P4, N=73, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2017 --> Dec 2017 Recruiting --> Completed
- everolimus / Generic mfg.
Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Oct 2, 2017
P2, N=4, Active, not recruiting, Sponsor: Emory University
Recruiting --> Completed Trial primary completion date: Sep 2017 --> Sep 2018
- | tamoxifen / Generic mfg.
Retrospective data, Journal: Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? (Pubmed Central) - Sep 29, 2017
While surgery remains the mainstay of treatment, chemotherapy may not be necessary in patients with advanced-stage disease who receive adjuvant hormonal therapy. A cooperative group, Phase III trial is planned to define the optimal therapy for women with this ovarian carcinoma subtype.
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Sep 29, 2017
P1, N=26, Active, not recruiting, Sponsor: Pfizer
A cooperative group, Phase III trial is planned to define the optimal therapy for women with this ovarian carcinoma subtype. Trial primary completion date: Dec 2017 --> Jun 2018
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] (clinicaltrials.gov) - Sep 29, 2017
P3, N=330, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Apr 2018 --> Mar 2019
- | denifanstat (TVB-2640) / Sagimet Biosci
Enrollment open: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Sep 27, 2017
P2, N=80, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Apr 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- || taselisib (GDC-0032) / Roche
Trial primary completion date: A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) (clinicaltrials.gov) - Sep 25, 2017
P2, N=334, Completed, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2017 --> Sep 2017
- | letrozole / Generic mfg.
Trial primary completion date: COAT: Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy (clinicaltrials.gov) - Sep 21, 2017
P2, N=300, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: May 2017 --> May 2018
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Sep 20, 2017
P2, N=259, Recruiting, Sponsor: Palleos Healthcare GmbH
Trial primary completion date: May 2017 --> May 2018 Not yet recruiting --> Recruiting